Dupilumab (Dupixent®) for the treatment of severe Atopic Dermatitis on the PBS - 7 October 2020

Allergy & Anaphylaxis Australia (A&AA) understands that Dupixent duplimab1Dupilumab (Dupixent®) for the treatment of people with severe atopic dermatitis (eczema) has been listed for another Pharmaceutical Benefits Advisory Committee (PBAC) hearing in November 2020. This listing is to assist the government and Sanofi-Aventis Australia (the sponsor of the new medication) with progression of Pharmaceutical Benefits Scheme listing of Dupilumab.

Australians with severe atopic dermatitis that have not responded to topical treatments have been arduously, yet patiently, waiting to access the medication at an affordable cost. Many are desperate and this added step of going back to the PBAC is being seen as a set back. Our hope is that the November PBAC meeting outcome means PBS listing will then be expedited. People with severe atopic dermatitis see this new medication as a lifeline and we are doing what we can to advocate for those waiting to access it.

We understand the impact severe atopic dermatitis has on the health and wellbeing of those living with this disease and their loved ones and we continue to strongly advocate for listing of this treatment, which has been available overseas for a number of years.

While we are confident the recommendation for PBS listing of Dupilumab will stand, we are writing to the Hon Greg Hunt, Minister for Health and to Sanofi-Aventis Australia to express our frustration and plea that the challenges preventing the urgent PBS listing of Dupilumab are resolved. People need to access the potentially life changing medication they so desperately need. 

Although public submission for the November PBAC meeting close today, we encourage people to voice their concerns even if outside this time frame. 

If you or someone you care about needs access to Dupilumab on the PBS we encourage you to write to your local MP telling your story and asking for this listing to be expedited. We will continue to advocate on behalf of all with severe atopic dermatitis. 

If this news causes you distress, please reach out to your GP or specialist for assistance or contact one of the mental health helplines listed here.

Acute Anaphylaxis CSS
Acute Anaphylaxis Clinical Care Standard - Learn more...
Atopic Dermatitis
allergy250K teens/young adults
Food allergy training

Our Supporters

Diamond


Viatris
Sanofi
Nestle
Allergy Concepts

Platinum


  • Bulla
  • NSW Food Authority
  • Novartis
  • Pfizer

Gold


  • dbv technologies
  • Mondelez
  • Nurticia
Silver

  • abbvie
  • Australian Camps Association
  • Bayer
  • Sanctuary Early Learning
  • Sweet William


© 2023 ALLERGY & ANAPHYLAXIS AUSTRALIA
ABN: 70 693 242 620

 



ALLERGY & ANAPHYLAXIS AUSTRALIA
is supported by funding from the
Australian Government,
Department of Health.


ALLERGY & ANAPHYLAXIS AUSTRALIA acknowledges and pays respect to the traditional custodians of the lands on which we work, live and play.

IN AN EMERGENCY

If you are having an allergic reaction follow advice on your ASCIA Action Plan.

If in doubt, give the Anapen® or EpiPen®.

Do not call us for emergency advice.

If you do not have an ASCIA Action Plan and/or an Anapen® or EpiPen® call triple zero (000) for an ambulance.